[Clinical evaluation of cefotetan in pediatrics].
Pharmacokinetic and clinical studies on cefotetan (CTT), a new cephamycin antibiotic, were carried out and the following results were obtained. Pharmacokinetic study Two patients, 7 years and 10 months of age (22 kg of body weight) and 9 years of age (28 kg of body weight), were administered 20 mg/kg of CTT by 30 minutes intravenous drip infusion. Serum levels of CTT were 148 micrograms/ml and 92 micrograms/ml immediately after the end of drip, 118 micrograms/ml and 63 micrograms/ml at 1 hour after the drip infusion. 76 micrograms/ml and 39 micrograms/ml at 2 hours after, 34 micrograms/ml and 18.2 micrograms/ml at 4 hours after and 18 micrograms/ml and 8.2 micrograms/ml at 6 hours after. Serum half-lives calculated were 1.92 hours and 1.78 hours respectively. Clinical study CTT was administered to a total of 14 patients, 3 with pneumonia, 2 with acute pyelonephritis, 2 with acute enteritis, each one with acute tonsillitis, acute bronchitis, acute bronchiolitis, sepsis, acute lymphadenitis, stomatitis and measles. Because that stomatitis and measles, however, were not indications of CTT, 2 cases with those diseases were excluded. CTT was administered at daily dose of 40 to 73 mg/kg in 2 to 4 portions for 3 to 5.5 days by intravenous drip infusion. Marked response was seen in 2 cases, moderate response in 9 and no response in 1, thus effectiveness rate was 91.7%. Neither side effects nor abnormal clinical laboratory findings were observed.
D000367:Age Factors; D001424:Bacterial Infections / Q000188:drug therapy*; D015313:Cefotetan; D002513:Cephamycins / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007263:Infusions, Parenteral; D008297:Male
D002513:Cephamycins; D015313:Cefotetan